Welcome!

News Feed Item

TNI BioTech Inc. Announces First Shipment of Lodonal® to The Republic of Panama and The Republic of Malawi

ORLANDO, Fla, Aug. 27, 2014 /PRNewswire/ -- TNI BioTech Inc. (OTCQB: TNIB), ("we" or the "Company") a biotechnology company pioneering the manufacturing and marketing of innovative therapies for autoimmune diseases in emerging nations, today announced it had received payment and will make its first shipments of Lodonal® to the Republic of Panama and The Republic of Malawi in conjunction with our marketing partner, The Brewer Group, Inc.

Commenting on the initial shipments, Noreen Griffin, CEO of TNI BioTech, stated, "Extensive work has been conducted and funds spent over the last twelve months obtaining local regulatory approval preparing for the launch of Lodonal® in these markets including participation at health conferences, drug dossiers, clinical case studies and training for sales professionals. We are confident that our distributors and sales teams are well positioned to establish Lodonal® as a major competitor in the treatment of cancer and autoimmune diseases in emerging nations. We are looking forward to launching Lodonal® in additional markets in the fourth quarter of 2014."   

Lodonal® is an active immunotherapy with low dose naltrexone (LDN), an oral medication that works by activating a patient's immune system against HIV/AIDS and tumor cells or by rebalancing the immune system of patients with autoimmune diseases with no toxic side effects.

Lodonal® competes in the advanced cancer and autoimmune drug market. Global Industry Analysis, Inc. recently released a comprehensive global report on the Autoimmune Disease Therapeutics market, which stated that the global market for Autoimmune Disease Therapeutics is projected to exceed US$77 billion by the year 2017, driven by the rising incidence of autoimmune complications worldwide. We believe that Lodonal® has demonstrated potential clinical and economic advantages over existing treatments for a number of chronic and acute autoimmune diseases, such as HIV/AIDS, certain cancers, rheumatoid arthritis, multiple sclerosis, Crohn's Disease and inflammatory bowel disease.

TNIB previously announced the launch of Lodonal® sales through PanAm Global Logistics, Inc. in conjunction with The Brewer Group, Inc. to the Republic of Malawi, Africa. "We are very excited to work with PanAm to begin distributing Lodonal® in Africa," stated His Excellency Ambassador Jack Brewer, founder and CEO of The Brewer Group. "The Brewer Group strives to serve a global vision with a social focus through all our advisory work and this opportunity to spread awareness for Lodonal® in emerging markets exemplifies the power of our mission.  We will immediately save lives by providing access to a trusted and affordable therapy to those living in the poorest areas in the world who are suffering from cancer and other autoimmune diseases."

In June 2014, TNIB announced the signing of a distribution agreement for the non-exclusive distribution of Lodonal® into Malawi, Panama, Sri Lanka, Egypt, Malaysia and Haiti.  With this sale, TNIB, through it is wholly owned subsidiary Airmed Biopharma Limited, will begin monthly shipments under the existing agreement. TNIB anticipates revenue of $1,800,000 dollars over the next twelve months. 

"We're very happy with the relationship that we've created with both PanAm Global Logistics, Inc and The Brewer Group, as this is an important step in implementing our international marketing and distribution program," said Noreen Griffin, CEO of TNI BioTech.

About TNI BioTech, Inc.

TNI BioTech is a biotechnology company working to combat chronic, life-threatening diseases through the activation and modulation of the body's immune system using our patented immunotherapy. Our products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases.

Our proprietary technology, therapies and patents include the treatment of a wide range of cancers. Our most advanced clinical programs involve immunotherapy with met-enkephalin ("MENK") (sometimes referred to as opioid growth factor ("OGF")) and our Low Dose Naltrexone product ("LDN") or Lodonal™, which have been shown to stimulate the immune system even in patients with advanced cancer.

Even though Management considers any condition that results in altered-immune response a target for investigation, the Company will most likely pursue additional investigations for MENK and LDN as valuable candidates in the treatment of autoimmune states such as rheumatoid arthritis and multiple sclerosis; as an adjunct in cancer patients undergoing chemotherapy, radiation treatments or surgery; and as a complement to antibiotics in the treatment of a variety of infectious diseases, including patients with HIV/AIDS, in combination with retroviral drug therapy.

About Airmed Biopharma Limited

Airmed Biopharma Limited, a wholly owned Irish company, is the pharmaceutical sales division of TNI BioTech. Airmed is responsible for servicing sales orders for Lodonal® in countries where TNI BioTech has received sales approval.

About Cytocom, Inc.

Cytocom, Inc. is a biotechnology company that will initially focus on developing Low Dose Naltrexone (Lodonal®) and met-enkephalin in the investigation of unmet medical needs in the areas of oncological and inflammatory diseases.

About The Brewer Group, Inc.

Established in 2005, The Brewer Group  is a multi-faceted global investment advisory firm focused on providing tailored services including capital markets, asset management, specialty finance and business development for public and private companies as well as high-profile clientele including athletes, entertainers and world leaders. TBG specializes in multiple sectors including: financial services; biotechnology & healthcare; sports; media & entertainment; wearable technology & consumer products; sustainable technology & agriculture; education & cultural exchange; and hospitality. The Brewer Group's relationships with high-profile clientele and affiliates including United Nations representatives, global organizations, distribution outlets, governments, key government and non-governmental officials, NPOs, agencies and unions as well as with various public and private corporations and international organizations place TBG in a unique position to execute a wide range of services around the globe. Additionally, The Brewer Group supports a 501(c)(3) non-profit organization, The Jack Brewer Foundation (JBF Worldwide), which uses its various programs and global initiatives to offer educational opportunities and economic development to underprivileged individuals around the world and its Chief Executive Officer, Jack Brewer, also serves as an Ambassador for Peace and Sport for the US Federation of Middle East Peace (USFMEP) at the United Nations. For further information, please visit www.thebrewergroup.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS


This press release and the statements of representatives and partners of the Company related thereto include various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which represent the Company's expectations or beliefs concerning future events. Statements containing expressions such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" used in the Company's press releases and in the Company's filings with the Securities and Exchange Commission as well as Disclosure Statements and Reports filed with the Over The Counter Markets through the OTC Disclosure and News Service are intended to identify forward-looking statements. All forward-looking statements involve assumptions and significant risks and uncertainties. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release, and thus readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date thereof. Actual results may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly release any revisions to such forward-looking statements to reflect events or circumstances after the date hereof.

For further information, please see http://www.tnibiotech.com

Contact: Dennis S. Dobson, 203-258-0159

 

 

 

 

SOURCE TNI BioTech, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The Internet giants are fully embracing AI. All the services they offer to their customers are aimed at drawing a map of the world with the data they get. The AIs from these companies are used to build disruptive approaches that cannot be used by established enterprises, which are threatened by these disruptions. However, most leaders underestimate the effect this will have on their businesses. In his session at 21st Cloud Expo, Rene Buest, Director Market Research & Technology Evangelism at Ara...
In his session at @ThingsExpo, Eric Lachapelle, CEO of the Professional Evaluation and Certification Board (PECB), provided an overview of various initiatives to certify the security of connected devices and future trends in ensuring public trust of IoT. Eric Lachapelle is the Chief Executive Officer of the Professional Evaluation and Certification Board (PECB), an international certification body. His role is to help companies and individuals to achieve professional, accredited and worldwide re...
It is ironic, but perhaps not unexpected, that many organizations who want the benefits of using an Agile approach to deliver software use a waterfall approach to adopting Agile practices: they form plans, they set milestones, and they measure progress by how many teams they have engaged. Old habits die hard, but like most waterfall software projects, most waterfall-style Agile adoption efforts fail to produce the results desired. The problem is that to get the results they want, they have to ch...
Cloud Expo, Inc. has announced today that Andi Mann and Aruna Ravichandran have been named Co-Chairs of @DevOpsSummit at Cloud Expo Silicon Valley which will take place Oct. 31-Nov. 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. "DevOps is at the intersection of technology and business-optimizing tools, organizations and processes to bring measurable improvements in productivity and profitability," said Aruna Ravichandran, vice president, DevOps product and solutions marketing...
Wooed by the promise of faster innovation, lower TCO, and greater agility, businesses of every shape and size have embraced the cloud at every layer of the IT stack – from apps to file sharing to infrastructure. The typical organization currently uses more than a dozen sanctioned cloud apps and will shift more than half of all workloads to the cloud by 2018. Such cloud investments have delivered measurable benefits. But they’ve also resulted in some unintended side-effects: complexity and risk. ...
"Loom is applying artificial intelligence and machine learning into the entire log analysis process, from start to finish and at the end you will get a human touch,” explained Sabo Taylor Diab, Vice President, Marketing at Loom Systems, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We are a monitoring company. We work with Salesforce, BBC, and quite a few other big logos. We basically provide monitoring for them, structure for their cloud services and we fit into the DevOps world" explained David Gildeh, Co-founder and CEO of Outlyer, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
21st International Cloud Expo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Me...
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend 21st Cloud Expo October 31 - November 2, 2017, at the Santa Clara Convention Center, CA, and June 12-14, 2018, at the Javits Center in New York City, NY, and learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.
SYS-CON Events announced today that Enzu will exhibit at SYS-CON's 21st Int\ernational Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Enzu’s mission is to be the leading provider of enterprise cloud solutions worldwide. Enzu enables online businesses to use its IT infrastructure to their competitive advantage. By offering a suite of proven hosting and management services, Enzu wants companies to focus on the core of their ...
In 2014, Amazon announced a new form of compute called Lambda. We didn't know it at the time, but this represented a fundamental shift in what we expect from cloud computing. Now, all of the major cloud computing vendors want to take part in this disruptive technology. In his session at 20th Cloud Expo, Doug Vanderweide, an instructor at Linux Academy, discussed why major players like AWS, Microsoft Azure, IBM Bluemix, and Google Cloud Platform are all trying to sidestep VMs and containers wit...
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend 21st Cloud Expo October 31 - November 2, 2017, at the Santa Clara Convention Center, CA, and June 12-14, 2018, at the Javits Center in New York City, NY, and learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.
DevOps at Cloud Expo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to w...
Internet of @ThingsExpo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devic...
Amazon started as an online bookseller 20 years ago. Since then, it has evolved into a technology juggernaut that has disrupted multiple markets and industries and touches many aspects of our lives. It is a relentless technology and business model innovator driving disruption throughout numerous ecosystems. Amazon’s AWS revenues alone are approaching $16B a year making it one of the largest IT companies in the world. With dominant offerings in Cloud, IoT, eCommerce, Big Data, AI, Digital Assista...